Webinar: Clinical value of cystatin C in drug dosing

24. Feb 2021 | 5 min read

Webinar: Clinical value of cystatin C in drug dosing

Clinical value of predicting renal elimination of medications with cystatin C

Welcome to the fourth webinar in Gentian's cystatin C webinar series. Our US Product Specialist, Shanyil Wickramasinghe, will focus on two real-world scenarios to illustrate the clinical value of incorporating cystatin C testing into medication dosing and monitoring protocols:

  • Personalising chemotherapeutic interventions through co-reporting of cystatin C and creatinine-based eGFRs

  • Cystatin C-guided dosing of vancomycin: A novel approach to achieving trough concentrations among ICU patients

Data presented in this webinar is collected from publications of independent research1-10.


Watch the webinar here: 

Cystatin C and drugdosing_webinar 9102v01

Watch webinar here

Contact Gentian - Cystatin C

Get in touch with our Product Manager for cystatin C for product specification and pricing:



Cystatin C immunoassay brochure



  1. McMahon, BA and MH Rosner. GFR Measurement and Chemotherapy Dosing in Patients with Kidney Disease and Cancer, in Kidney360, 2020. 
  2. Santos, MLC et al. Nephrotoxicity in cancer treatment: An overview, in World J Clin Oncol, 2020. 
  3. Orth, M et al. Avoiding Insufficient Therapies and Overdosing with Co-Reporting eGFRs for Personalized Drug Therapy and Improved Outcomes, in ACHIEVING MEASURABLY BETTER HEALTHCARE PERFORMANCE, 2019.
  4. Frazee, EN et al. Serum cystatin C predicts vancomycin trough levels better than serum creatinine in hospitalized patients: a cohort study, in Crit Care, 2014. 
  5. Begg, EJ, ML Barclay and CJ Kirkpatrick. The therapeutic monitoring of antimicrobial agents, in Br J Clin Pharmacol, 1999. 
  6. Levine, DP. Vancomycin: a history, in Clin Infect Dis, 2006. 
  7. FDA, Guidance for Industry Pharmacokinetics in Patients with Impaired Renal Function - Study Design, Data Analysis, and Impact on Dosing, DHHS, Editor. 2020: www.fda.gov.
  8. Frazee, E et al. Cystatin C-Guided Vancomycin Dosing in Critically Ill Patients: A Quality Improvement Project, in Am J Kidney Dis, 2017.
  9. Kullar, R et al. Effects of targeting higher vancomycin trough levels on clinical outcomes and costs in a matched patient cohort, in Pharmacotherapy, 2012. 
  10. Lloyd-Smith, P et al. Economic analysis of vancomycin-resistant enterococci at a Canadian hospital: assessing attributable cost and length of stay, in J Hosp Infect, 2013. 

You may also read

FAQ: What is the value of calprotectin in blood as biomarker in IBD?

May 19, 2022

FAQ: What is the value of calprotectin in blood as biomarker in IBD?

In our Frequently Asked Questions about calprotectin series we will answer questions we often receive about..

Available position: Finance Manager - Norway based

May 14, 2022

Available position: Finance Manager - Norway based

Text in Norwegian: Vi er på utkikk etter en selvgående Finance Manager som vil få ansvar for rapportering på..

Webinar: Calprotectin in infections

May 11, 2022

Webinar: Calprotectin in infections

Webinar: Calprotectin in infections The webinar “Calprotectin in infections” looks into calprotectin’s role..